Physician

Owolabi Ogunneye, M.D.FRCP(UK)

According to 2025 Medicare claims, Owolabi Ogunneye, M.D.FRCP(UK) (NPI: 1992011472) practices nephrology in the Saginaw, MI market, with the plurality of this provider's patient population coming from Saginaw, MI. This provider's primary affiliated billing organization is KIDNEY DISEASE & HYPERTENSION CONSULTANTS PC (NPI: 1548329683; TIN: 20-5917382) and primary practice location at 48602-4727. Ogunneye is affiliated with the McLaren High Performance Network, LLC (ACO ID: A3317), Mosaic ACO (ACO ID: A5033), and Aledade 155 National MSSP (ACO ID: A5358), participating under the MSSP model.

Ogunneye's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 459 traditional Medicare patients, billed 1,683 HCPCS/CPT codes, and received $165,734 in Medicare payments. The top billing code was 99222 (Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes). Part D data shows 3,254 prescription claims across 627 beneficiaries totaling $1,034,915 in drug costs, led by Ozempic (Semaglutide). 2021 DME data shows 52 claims. Open Payments data shows 27 records totaling $606. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $17,697 to $1,034,915. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	174	521	$35,423
2016	606	1,966	$128,090
2017	807	2,879	$210,703
2018	796	3,046	$248,049
2019	938	3,653	$335,988
2020	740	3,070	$308,718
2021	750	3,207	$333,912
2022	625	2,704	$287,635
2023	562	2,283	$250,834
2024	459	1,683	$165,734

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	146	565	$17,697
2016	360	1,778	$86,731
2017	345	1,637	$115,023
2018	480	2,082	$146,595
2019	576	2,406	$134,470
2020	541	2,965	$196,182
2021	558	2,827	$245,144
2022	612	3,127	$338,963
2023	631	3,091	$779,719
2024	627	3,254	$1,034,915

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	80	$4,065
2017	N/R	44	$2,616
2018	N/R	11	$1,514
2019	N/R	23	$1,594
2020	N/R	N/R	N/R
2021	N/R	52	$1,686
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	85	92	$99
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	99	192	$90
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	116	131	$80
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	236	704	$60
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	91	108	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ozempic	Semaglutide	250	8,560	$270,505
Jardiance	Empagliflozin	176	10,501	$195,664
Mounjaro	Tirzepatide	104	3,500	$126,856
Trulicity	Dulaglutide	91	2,772	$91,723
Farxiga	Dapagliflozin Propanediol	65	3,820	$71,449

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	27	$606	Fresenius USA Marketing, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Owolabi Ogunneye, M.D.FRCP(UK)?

Tedicare shows public-source Medicare data for Owolabi Ogunneye, M.D.FRCP(UK) (NPI 1992011472), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Owolabi Ogunneye, M.D.FRCP(UK) have ACO affiliation data?

Owolabi Ogunneye, M.D.FRCP(UK) is shown with ACO affiliation data for McLaren High Performance Network, LLC (MSSP, ACO ID A3317), Mosaic ACO (MSSP, ACO ID A5033), and Aledade 155 National MSSP (MSSP, ACO ID A5358).

What billing organization is linked to Owolabi Ogunneye, M.D.FRCP(UK)?

Owolabi Ogunneye, M.D.FRCP(UK) is linked to KIDNEY DISEASE & HYPERTENSION CONSULTANTS PC (billing NPI 1548329683) in the available physician profile data.

Does Owolabi Ogunneye, M.D.FRCP(UK) have Open Payments data?

Owolabi Ogunneye, M.D.FRCP(UK) has 27 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.